Transferrin receptor-targeted liposomes encapsulating anti-BCR-ABL siRNA or asodn for chronic myeloid leukemia treatment

Bioconjugate Chemistry

Volumn 21, Issue 1, 2010, Pages 157-168

  Mendonça, Liliana S ^a,b   Firmino, Filipe ^b   Moreira, João N ^a,b   De Lima, Maria C Pedroso ^b,c   Simões, Sérgio ^a,b  

^a UNIVERSITY OF COIMBRA   (Portugal)

^b UNIVERSITY OF COIMBRA   (Portugal)

^c UNIVERSITY OF COIMBRA   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

CELL CULTURE; CELLS; DISEASES; POLYMERASE CHAIN REACTION; PROTEINS;

CELL ASSOCIATIONS; CELL INTERNALIZATION; CELL VIABILITY; CHRONIC MYELOID LEUKEMIAS; DEVELOPMENT AND APPLICATIONS; ENCAPSULATION YIELDS; NON-TARGETED; PROTEIN LEVEL; STERICALLY STABILIZED LIPOSOMES; TRANSFERRIN RECEPTORS;

LIPOSOMES;

ALBUMIN; ANTISENSE OLIGONUCLEOTIDE; BCR ABL PROTEIN; BREAKPOINT CLUSTER REGION PROTEIN; LIPOSOME; MESSENGER RNA; NUCLEIC ACID; RESAZURIN; SMALL INTERFERING RNA; TRANSFERRIN RECEPTOR;

ARTICLE; CELL VIABILITY; CHRONIC MYELOID LEUKEMIA; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; ENCAPSULATION; FLOW CYTOMETRY; GENE SILENCING; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

EID: 74949127407     PISSN: 10431802     EISSN: None     Source Type: Journal    
DOI: 10.1021/bc9004365     Document Type: Article

References (53)

1. Pasternak, G., Hochhaus, A., Schultheis, B., and Hehlmann, R. (1998) Chronic myelogenous leukemia: molecular and cellular aspects. J. Cancer Res. Clin. Oncol. 124, 643-60.
2. Goldman, J. M. (2004) Chronic myeloid leukemia-still a few questions. Exp. Hematol. 32, 2-10.
3. Savona, M., and Talpaz, M. (2008) Getting to the stem of chronic myeloid leukaemia. Nat. Rev. Cancer 8, 341-50.
4. Galderisi, U., Cascino, A., and Giordano, A. (1999) Antisense oligonucleotides as therapeutic agents. J. Cell Physiol. 181, 251-7.
5. Tamm, I. (2006) Antisense therapy in malignant diseases: status quo and quo vadis? Clin. Sci. (London) 110, 427-42.
6. Dykxhoorn, D. M., Palliser, D., and Lieberman, J. (2006) The silent treatment: siRNAs as small molecule drugs. Gene Ther. 13, 541-52.
7. Dykxhoorn, D. M., Novina, C. D., and Sharp, P. A. (2003) Killing the messenger: short RNAs that silence gene expression. Nat. Rev. Mol. Cell Biol. 4, 457-67.
8. Huang, C., Li, M., Chen, C., and Yao, Q. (2008) Small interfering RNA therapy in cancer: mechanism, potential targets, and clinical applications. Expert Opin. Ther. Targets 12, 637-45.
9. Kumar, L. D., and Clarke, A. R. (2007) Gene manipulation through the use of small interfering RNA (siRNA): from in vitro to in vivo applications. Adv. Drug Delivery Rev. 59, 87-100.
10. Kawakami, S., and Hashida, M. (2007) Targeted delivery systems of small interfering RNA by systemic administration. Drug Metab. Pharmacokinet. 22, 142-51.
11. Zhang, C., Tang, N., Liu, X., Liang, W., Xu, W., and Torchilin, V. P. (2006) siRNA-containing liposomes modified with polyarginine effectively silence the targeted gene. J. Controlled Release 112, 229-39.
12. Akhtar, S., and Benter, I. (2007) Toxicogenomics of nonviral drug delivery systems for RNAi: potential impact on siRNA-mediated gene silencing activity and specificity. Adv. Drug Delivery Rev. 59, 164-82.
13. Mahato, R. I., Cheng, K., and Guntaka, R. V. (2005) Modulation of gene expression by antisense and antigene oligodeoxynucleotides and small interfering RNA. Expert Opin. Drug Delivery 2, 3-28.
14. Patil, S. D., Rhodes, D. G., and Burgess, D. J. (2005) DNA-based therapeutics and DNA delivery systems: a comprehensive review. AAPS J. 7, E61-77.
15. Daniels, T. R., Delgado, T., Rodriguez, J. A., Helguera, G., and Penichet, M. L. (2006) The transferrin receptor part I: Biology and targeting with cytotoxic antibodies for the treatment of cancer. Clin. Immunol. 121, 144-58.
16. Li, H., and Qian, Z. M. (2002) Transferrin/transferrin receptor-mediated drug delivery. Med. Res. Rev. 22, 225-50.
17. Ponka, P., and Lok, C. N. (1999) The transferrin receptor: role in health and disease. Int. J. Biochem. Cell Biol. 31, 1111-37.
18. Visser, C. C., Stevanovic, S., Voorwinden, L. H., van Bloois, L., Gaillard, P. J., Danhof, M., Crommelin, D. J., and de Boer, A. G. (2005) Targeting liposomes with protein drugs to the bloodbrain barrier in vitro. Eur. J. Pharm. Sci. 25, 299-305.
19. Chiu, S. J., Liu, S., Perrotti, D., Marcucci, G., and Lee, R. J. (2006) Efficient delivery of a Bcl-2-specific antisense oligodeoxyribonucleotide (G3139) via transferrin receptor-targeted liposomes. J. Controlled Release 112, 199-207.
20. Daniels, T. R., Delgado, T., Helguera, G., and Penichet, M. L. (2006) The transferrin receptor part II: targeted delivery of therapeutic agents into cancer cells. Clin. Immunol. 121, 159-76.
21. Immordino, M. L., Dosio, F., and Cattel, L. (2006) Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential. Int. J. Nanomed. 1, 297-315.
22. Romberg, B., Hennink, W. E., and Storm, G. (2008) Sheddable coatings for long-circulating nanoparticles. Pharm. Res. 25, 55-71.
23. Ryan, S. M., Mantovani, G., Wang, X., Haddleton, D. M., and Brayden, D. J. (2008) Advances in PEGylation of important biotech molecules: delivery aspects. Expert Opin. Drug Delivery 5, 371-83.
24. Ishida, T., Iden, D. L., and Allen, T. M. (1999) A combinatorial approach to producing sterically stabilized (Stealth) immunoliposomal drugs. FEBS Lett. 460, 129-33.
25. O'Brien, J., Wilson, I., Orton, T., and Pognan, F. (2000) Investigation of the Alamar Blue (resazurin) fluorescent dye for the assessment of mammalian cell cytotoxicity. Eur. J. Biochem. 267, 5421-6.
26. Beillard, E., Pallisgaard, N., van der Velden, V. H., Bi, W., Dee, R., van der Schoot, E., Delabesse, E., Macintyre, E., Gottardi, E., Saglio, G., Watzinger, F., Lion, T., van Dongen, J. J., Hokland, P., and Gabert, J. (2003) Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using 'real-time' quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) - a Europe against cancer program. Leukemia 17, 2474-86.
27. Gabert, J., Beillard, E., van der Velden, V. H., Bi, W., Grimwade, D., Pallisgaard, N., Barbany, G., Cazzaniga, G., Cayuela, J. M., Cave, H., Pane, F., Aerts, J. L., De Micheli, D., Thirion, X., Pradel, V., Gonzalez, M., Viehmann, S., Malec, M., Saglio, G., and van Dongen, J. J. (2003) Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program. Leukemia 17, 2318-57.
28. Cardoso, A. L., Simoes, S., de Almeida, L. P., Plesnila, N., Pedroso de Lima, M. C., Wagner, E., and Culmsee, C. (2008) Tf-lipoplexes for neuronal siRNA delivery: a promising system to mediate gene silencing in the CNS. J. Controlled Release 132, 113-23.
29. Semple, S. C., Klimuk, S. K., Harasym, T. O., Dos Santos, N., Ansell, S. M., Wong, K. F., Maurer, N., Stark, H., Cullis, P. R., Hope, M. J., and Scherrer, P. (2001) Efficient encapsulation of antisense oligonucleotides in lipid vesicles using ionizable aminolipids: formation of novel small multilamellar vesicle structures. Biochim. Biophys. Acta 1510, 152-66.
30. Maurer, N., Wong, K. F., Stark, H., Louie, L., McIntosh, D., Wong, T., Scherrer, P., Semple, S. C., and Cullis, P. R. (2001) Spontaneous entrapment of polynucleotides upon electrostatic interaction with ethanol-destabilized cationic liposomes. Biophys. J. 80, 2310-26.
31. Kalota, A., Shetzline, S. E., and Gewirtz, A. M. (2004) Progress in the development of nucleic acid therapeutics for cancer. Cancer Biol. Ther. 3, 4-12.
32. Pedroso de Lima, M. C., Simoes, S., Pires, P., Faneca, H., and Duzgunes, N. (2001) Cationic lipid-DNA complexes in gene delivery: from biophysics to biological applications. Adv. Drug Delivery Rev. 47, 277-94.
33. Lv, H., Zhang, S., Wang, B., Cui, S., and Yan, J. (2006) Toxicity of cationic lipids and cationic polymers in gene delivery. J. Controlled Release 114, 100-9.
34. Morille, M., Passirani, C., Vonarbourg, A., Clavreul, A., and Benoit, J. P. (2008) Progress in developing cationic vectors for non-viral systemic gene therapy against cancer. Biomaterials 29, 3477-96.
35. Simoes, S., Filipe, A., Faneca, H., Mano, M., Penacho, N., Duzgunes, N., and de Lima, M. P. (2005) Cationic liposomes for gene delivery. Expert Opin. Drug Delivery 2, 237-54.
36. Dass, C. R., and Choong, P. F. (2006) Selective gene delivery for cancer therapy using cationic liposomes: in vivo proof of applicability. J. Controlled Release 113, 155-63.
37. Morrissey, D. V., Lockridge, J. A., Shaw, L., Blanchard, K., Jensen, K., Breen, W., Hartsough, K., Machemer, L., Radka, S., Jadhav, V., Vaish, N., Zinnen, S., Vargeese, C., Bowman, K., Shaffer, C. S., Jeffs, L. B., Judge, A., MacLachlan, I., and Polisky, B. (2005) Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nat. Biotechnol. 23, 1002-7.
38. Semple, S. C., Harasym, T. O., Clow, K. A., Ansell, S. M., Klimuk, S. K., and Hope, M. J. (2005) Immunogenicity and rapid blood clearance of liposomes containing polyethylene glycollipid conjugates and nucleic Acid. J. Pharmacol. Exp. Ther. 312, 1020-6.
39. Mui, B., Raney, S. G., Semple, S. C., and Hope, M. J. (2001) Immune stimulation by a CpG-containing oligodeoxynucleotide is enhanced when encapsulated and delivered in lipid particles. J. Pharmacol. Exp. Ther. 298, 1185-92.
40. Stuart, D. D., Semple, S. C., and Allen, T. M. (2004) High efficiency entrapment of antisense oligonucleotides in liposomes. Methods Enzymol. 387, 171-88.
41. Takasaki, J., Raney, S. G., Chikh, G., Sekirov, L., Brodsky, I., Tam, Y., and Ansell, S. M. (2006) Methods for the preparation of protein- oligonucleotide-lipid constructs. Bioconjugate Chem. 17, 451-8.
42. Uster, P. S., Allen, T. M., Daniel, B. E., Mendez, C. J., Newman, M. S., and Zhu, G. Z. (1996) Insertion of poly(ethylene glycol) derivatized phospholipid into pre-formed liposomes results in prolonged in vivo circulation time. FEBS Lett. 386, 243-6.
43. Allen, T. M., Sapra, P., and Moase, E. (2002) Use of the postinsertion method for the formation of ligand-coupled liposomes. Cell. Mol. Biol. Lett. 7, 889-94.
44. Kim, S. H., Mok, H., Jeong, J. H., Kim, S. W., and Park, T. G. (2006) Comparative evaluation of target-specific GFP gene silencing efficiencies for antisense ODN, synthetic siRNA, and siRNA plasmid complexed with PEI-PEG-FOL conjugate. Bioconjugate Chem. 17, 241-4.
45. Grimm, D., Streetz, K. L., Jopling, C. L., Storm, T. A., Pandey, K., Davis, C. R., Marion, P., Salazar, F., and Kay, M. A. (2006) Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature 441, 537-41.
46. Reynolds, A., Anderson, E. M., Vermeulen, A., Fedorov, Y., Robinson, K., Leake, D., Karpilow, J., Marshall, W. S., and Khvorova, A. (2006) Induction of the interferon response by siRNA is cell type- and duplex length-dependent. RNA 12, 988-93.
47. Suggate, E. L., Ahmed, Z., Read, M. L., Eaton-Charnock, K., Douglas, M. R., Gonzalez, A. M., Berry, M., and Logan, A. (2009) Optimisation of siRNA-mediated RhoA silencing in neuronal cultures. Mol. Cell. Neurosci. 40, 451-62.
48. Bertrand, J. R., Pottier, M., Vekris, A., Opolon, P., Maksimenko, A., and Malvy, C. (2002) Comparison of antisense oligonucleotides and siRNAs in cell culture and in vivo. Biochem. Biophys. Res. Commun. 296, 1000-4.
49. Tschuch, C., Schulz, A., Pscherer, A., Werft, W., Benner, A., Hotz-Wagenblatt, A., Barrionuevo, L. S., Lichter, P., and Mertens, D. (2008) Off-target effects of siRNA specific for GFP. BMC Mol. Biol. 9, 60.
50. Tschaharganeh, D., Ehemann, V., Nussbaum, T., Schirmacher, P., and Breuhahn, K. (2007) Non-specific effects of siRNAs on tumor cells with implications on therapeutic applicability using RNA interference. Pathol. Oncol. Res. 13, 84-90.
51. Achenbach, T. V., Brunner, B., and Heermeier, K. (2003) Oligonucleotide-based knockdown technologies: antisense versus RNA interference. ChemBioChem 4, 928-35.
52. Hannon, G. J., and Rossi, J. J. (2004) Unlocking the potential of the human genome with RNA interference. Nature 431, 371-8.
53. Judge, A. D., Sood, V., Shaw, J. R., Fang, D., McClintock, K., and MacLachlan, I. (2005) Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA. Nat. Biotechnol. 23, 457-62.